A Phase 1 interventional study of Placebo and ECC0509 in Nonalcoholic Steatohepatitis and Osteoarthritis, sponsored by Eccogene. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-25.
Sponsored by Eccogene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia — 8 open to participants now, 12 under way, 10 of them phase 3. Non-alcoholic Fatty Liver Disease · Australia.
Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, this one is the 39th largest by enrollment, is one of 11 that started in 2021, is one of 15 in phase 1, and was the 38th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →8 of the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia are open now. Recruiting first, the newest first:
Eccogene · Sites in Australia
Ages 18–65 · Healthy volunteers
GlaxoSmithKline · Sites in Australia, United States, France and 5 more countries
Ages 18–75
GlaxoSmithKline · Sites in Australia, United States, Canada and 6 more countries
Ages 18–75
Eli Lilly and Company · Sites in Australia, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Australia, United States, Argentina and 20 more countries
Ages 18–80
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 23 · Phase 3 17
First in 2014; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 264 across the 54 interventional studies. Of the 40 that completed or were terminated, 24 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 54 have an industry lead sponsor. The 10 most frequent:
Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Eccogene has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-alcoholic Fatty Liver Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07726368EccogeneStudy of ECC4703 With Sulfasalazine and Pitavastatin | 2026-12 |
| NCT07873229EccogeneDDI Study of ECC0509 With Metformin, Midazolam, and Caffeine | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.
This study will be conducted in up to seven cohorts of Single Ascending Dose (SAD) \& 3 cohorts of Multiple Ascending Dose (MAD). SAD will consist of a staggered dosing approach with a dose range from 1mg to 80mg. Staggered dosing approach will not be deployed for MAD cohorts with a dose range of 8mg to 40mg. In the MAD cohort, the effect of food will also be assessed by comparing the PK profile of Day 10 fed conditions against Day 14 fasted conditions.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in each SAD cohort will be randomized to receive placebo.
Drug: Placebo
Participants in each SAD cohort will be randomized to receive 1 of 6 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, or 60 mg).
Drug: ECC0509
Participants will be randomized to receive a once-daily dose of placebo for 14 days.
Drug: Placebo
Participants will be randomized to receive a once-daily dose of 1 of 4 escalating doses (3 mg, 10 mg, 30 mg, 60 mg) for 14 days.
Drug: ECC0509
Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations
Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.
Time frame: SAD: Up to Day 8. MAD: Up to Day 21.
ECC0509 PK parameters: Cl/F
Apparent clearance
Time frame: SAD: Up to Day 8.
ECC0509 PK parameters: Vz/F
Apparent volume of distribution
Time frame: SAD: Up to Day 8.
ECC0509 PK parameter: AUC0-24
Area under the concentration-time curve from time zero to time 24 hours
Time frame: MAD: Up to Day 21
ECC0509 PK parameter: Cmax ss
Maximal observed concentration at steady-state
Time frame: MAD: Up to Day 21
ECC0509 PK parameter: Tmax ss
Time when the maximal concentration is observed at steady-state
Time frame: MAD: Up to Day 21
ECC0509 PK parameter: Tlag ss
Time prior to the first measurable (non-zero) concentration at steady-state
Time frame: MAD: Up to Day 21
ECC0509 PK parameters: Cmax
Maximal observed concentration
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
ECC0509 PK parameter: Tmax
Time when the maximal concentration is observed
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
ECC0509 PK parameter: AUC0-t
Area under the curve up to the last quantifiable time-point
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
ECC0509 PK parameter: Cmin ss
Minimal observed concentration at steady-state
Time frame: MAD: Up to Day 21
ECC0509 PK parameter: T½ el
Terminal elimination half-life
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
ECC0509 PK parameter: Kel
Terminal elimination rate constant
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
ECC0509 PK parameter: Clss/F
Apparent body clearance at steady-state
Time frame: MAD: Up to Day 21
ECC0509 PK parameter: Vz ss/F
Apparent volume of distribution at steady-state
Time frame: MAD: Up to Day 21
ECC0509 PK parameter: AUC0-τ
Area under the concentration-time curve for one dosing interval (τ) at steady state.
Time frame: MAD: Up to Day 21
ECC0509 PK parameters: AUC0-inf
Area under the concentration-time curve from time zero to infinity
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
ECC0509 PK parameters: Residual area
Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
PD Parameter: SSAO
plasma semicarbazide-sensitive amine oxidase (SSAO) activity.
Time frame: SAD: Up to Day 8. MAD: Up to Day 21.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Jul 2023, 23 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 23 months is above that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ECC0509
Non-alcoholic Fatty Liver Disease →
Eccogene